- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
ADVERTISEMENT
Brand Name :
Verzenio
Synonyms :
Abemaciclib
Class :
Antineoplastics and CDK Inhibitors
Dosage Forms & Strengths
Tablet
50mg
100mg
150mg
200mg
150
mg
Orally
twice a day
; when used with tamoxifen or an aromatase inhibitor
The treatment needs to be continued for two years until the disease progression or unacceptable toxicity occurs
Monotherapy :
200
mg
Orally
twice a day
The treatment needs to be continued for two years until the disease progression or unacceptable toxicity occurs
When used in combination therapy with an aromatase inhibitor
150 mg orally taken twice a day PLUS an aromatase inhibitor
The treatment needs to be continued for two years until the disease progression or unacceptable toxicity occurs
Note:
This combination is helpful for initial endocrine-based therapy for postmenopausal women and men with HR-positive, HER2-negative advanced or metastatic breast cancer
When used in combination therapy with fulvestrant
150 mg orally taken twice a day PLUS Fulvestrant 500 mg given IM as on days 1, 15, and 29, and continue this course once monthly after that
The treatment needs to be continued for two years until the disease progression or unacceptable toxicity occurs
Note:
This combination is helpful with fulvestrant for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may enhance the metabolism of clobetasol propionate
when both drugs are combined, there may be increase in the serum concentration of abemaciclib
when both drugs are combined, there may be increase in the serum concentration of abemaciclib
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs are combined, there may be a reduced blood level of abemaciclib and result in less effectiveness in treating cancer
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme CYP3A4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced metabolism of abemaciclib
when both drugs are combined, there may be a reduced metabolism of abemaciclib
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may reduce the level of serum concentration of abemaciclib
may reduce the level of serum concentration of abemaciclib
may reduce the level of serum concentration of abemaciclib
may reduce the level of serum concentration of abemaciclib
may reduce the level of serum concentration of abemaciclib
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
When nafcillin combines with abemaciclib, nafcillin will decrease the effect of action of abemaciclib by affecting enzyme CYP3A4 metabolism.
the effect of abemaciclib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be a decreased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of abemaciclib
CYP3A4 inducers decrease the concentration of abemaciclib in serum
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by p-glycoprotein -mdr1 efflux transporter
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme CYP3A4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased immunosuppressive effect of both drugs and a risk of infection
when both drugs are combined, there may be a reduced metabolism of abemaciclib
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism abem
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased immunosuppressive effect of both drugs and a risk of infection
when both drugs are combined, there may be an increased effect of abemaciclib by p-glycoprotein -mdr1 efflux transporter
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
may increase the serum concentration of abemaciclib
CYP3A4 Inhibitors (Moderate) may increase the serum concentration when combined with Abemaciclib
it may diminish the metabolism when combined with zuclopenthixol
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased level or effect of abemaciclib
fedratinib increases the effect of abemaciclib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
idelalisib increases the effect or level of abemaciclib by altering the intestinal/hepatic CYP3A4 metabolism
CYP3A4 inhibitors increase the concentration of abemaciclib in serum
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
Adverse drug reactions:
Frequency defined
>10%
Increased creatinine
Decreased white blood cell count
decreased neutrophil count
anemia
decreased lymphocyte count
decreased platelet count
neutropenia
Leukopenia
Thrombocytopenia
Diarrhea
nausea
abdominal pain
vomiting
constipation
stomatitis
dry mouth
Fatigue
infections
peripheral edema
Pyrexia
1-10%
Interstitial lung disease
Pneumonitis
Arthralgia
Venous thromboembolic events
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Abemaciclib is an anti-cancer agent used to treat breast cancer that may spread along with the lymph nodes of the armpit.
For the caution, abemaciclib may reduce the WBCs and put you at greater risk of infection. It may also cause blood clots in veins, affect liver functionality, and cause diarrhea.
This drug is not suitable for adolescents and children below 18 years.
The recommended dosage for breast cancer therapy is 150 mg orally twice daily.
The treatment of abemaciclib should last for two years.
Common side effects of abemaciclib may include dry skin, muscle weakness, watery eyes, indigestion, splitting of nails and inflammation in the lungs, hair loss, and decreased appetite.
Do not take a double dose if you miss a dose; take the next one at the usual time.
Keep the medicine out of reach of children. There are no special conditions required for storage.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
